Chronotherapeutic strategy: Rhythm monitoring, manipulation and disruption

Advanced Drug Delivery Reviews

Volumn 62, Issue 9-10, 2010, Pages 859-875

  Ohdo, Shigehiro ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Biological clock; Chrono DDS; Chronopharmacokinetics; Chronopharmacology; Chronotherapy; Circadian rhythm

Indexed keywords

BIOLOGICAL CLOCK; CHRONO-DDS; CHRONOPHARMACOKINETICS; CHRONOPHARMACOLOGY; CHRONOTHERAPY; CIRCADIAN RHYTHMS;

CLOCKS; DRUG DELIVERY; DRUG INTERACTIONS; DRUG PRODUCTS; GENES; PHARMACOKINETICS; PHYSIOLOGY;

PROCESS CONTROL;

ANTINEOPLASTIC AGENT; CISPLATIN; CORTICOSTEROID; DIAZEPAM; DILTIAZEM; DOXORUBICIN; FAMOTIDINE; FLUOROURACIL; FLUVOXAMINE; FOLINIC ACID; GLUCOCORTICOID; HALOPERIDOL; HOKUNALIN; HYDROCORTISONE; IMATINIB; INTERFERON; IRINOTECAN; MELATONIN; METHYLPREDNISOLONE; OXALIPLATIN; PROPRANOLOL; PSYCHOTROPIC AGENT; RISPERIDONE; SALICYLATE SODIUM; SIMVASTATIN; THEOPHYLLINE; TRANSCRIPTION FACTOR CLOCK; TULOBUTEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL;

BIOLOGICAL RHYTHM; CHRONOBIOLOGY; CHRONOPHARMACOLOGY; CHRONOTHERAPY; CIRCADIAN RHYTHM; CIRCADIAN RHYTHM SLEEP DISORDER; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; DELAYED SLEEP PHASE SYNDROME; DISEASE COURSE; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; EVENING DOSAGE; FOOD; FOOD DRUG INTERACTION; GILLES DE LA TOURETTE SYNDROME; HEART RATE; HUMAN; LYMPHOCYTOPENIA; MORNING DOSAGE; NOCTURNAL ASTHMA; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OVARY CANCER; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SARCOMA; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; STOMATITIS; SUPRACHIASMATIC NUCLEUS; UNSPECIFIED SIDE EFFECT;

ANIMALS; CIRCADIAN CLOCKS; CIRCADIAN RHYTHM SIGNALING PEPTIDES AND PROTEINS; DRUG ADMINISTRATION SCHEDULE; DRUG CHRONOTHERAPY; DRUG DELIVERY SYSTEMS; HUMANS; PHARMACEUTICAL PREPARATIONS; TIME FACTORS;

EID: 77955920975     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2010.01.006     Document Type: Review

References (113)

1. Moore R.Y., Eichler V.B. Loss of a circadian adrenal corticosterone rhythm following suprachiasmatic lesions in the rat. Brain Res. 1972, 42:201-206.
2. Tei H., Okamura H., Shigeyoshi Y., Fukuhara C., Ozawa R., Hirose M., Sakaki Y. Circadian oscillation of a mammalian homologue of the Drosophila period gene. Nature 1997, 389:512-516.
3. Jin X., Shearman L.P., Weaver D.R., Zylka M.J., de Vries G.J., Reppert S.M. A molecular mechanism regulating rhythmic output from the suprachiasmatic circadian clock. Cell 1999, 96:57-68.
4. Ozdemir V., Shear N.H., Kalow W. What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects?. Drug Safety 2001, 24:75-85.
5. Halberg F. Chronobiology. Annu. Rev. Physiol. 1969, 31:675-725.
6. Reinberg A., Halberg F. Circadian chronopharmacology. Annu. Rev. Pharmacol. 1971, 11:455-492.
7. Smolensky M.H., Labrecque G. Chronotherapeutics. Pharm News 1997, 4:10-16.
8. Ohdo S. Changes in toxicity and effectiveness with timing of drug administration. Implications for drug safety. Drug Safety 2003, 26(14):999-1010.
9. Ohdo S. Chronopharmaceutics: pharmaceutics focused on biological rhythm. Biol. Pharm. Bull. 2010, 33(2):159-167.
10. Ohdo S. Chronopharmacology focused on biological clock. Drug Metab. Pharmacokinet. 2007, 22(1):3-14.
11. Youan B.-B.C. Chronopharmaceutics: gimmick or clinically relevant approach to drug delivery?. J. Control. Rel. 2004, 98:337-353.
12. Duncan W.C. Circadian rhythms and the pharmacology of affective illness. Pharmacol. Ther. 1996, 71:253-312.
13. Ohdo S., Koyanagi S., Suyama H., Higuchi S., Aramaki H. Changing the dosing schedule minimizes the disruptive effects of interferon on clock function. Nat. Med. 2001, 7:356-360.
14. Chang D.C., Reppert S.M. The circadian clocks of mice and men. Neuron 2001, 29:555-558.
15. Sakamoto K., Nagase T., Fukui H., Horikawa K., Okada T., Tanaka H., Sato K., Miyake Y., Ohara O., Kako K., Ishida N. Multitissue circadian expression of rat period homolog (rPer2) mRNA is governed by the mammalian circadian clock, the suprachiasmatic nucleus in the brain. J. Biol. Chem. 1998, 273:27039-27042.
16. Ueyama T., Krout K.E., Nguyen X.V., Karpitskiy V., Kollert A., Mettenleiter T.C., Loewy A.D. Suprachiasmatic nucleus: a central autonomic clock. Nat. Neurosci. 1999, 2:1051-1053.
17. Silver R., LeSauter J., Tresco P.A., Lehman M.N. A diffusible coupling signal from the transplanted suprachiasmatic nucleus controlling circadian locomotor rhythms. Nature 1996, 382:810-813.
18. Jones C.R., Campbell S.S., Zone S.E., Cooper F., DeSano A., Murphy P.J., Jones B., Czajkowski L., Ptacek L.J. Familial advanced sleep-phase syndrome: a short-period circadian rhythm variant in humans. Nat. Med. 1999, 5:1062-1065.
19. Toh K.L., Jones C.R., He Y., Eide E.J., Hinz W.A., Virshup D.M., Ptacek L.J., Fu Y.H. An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome. Science 2001, 291:1040-1043.
20. Maemura K., de la Monte S.M., Chin M.T., Layne M.D., Hsieh C.M., Yet S.F., Perrella M.A., Lee M.E. CLIF, a novel cycle-like factor, regulates the circadian oscillation of plasminogen activator inhibitor-1 gene expression. J. Biol. Chem. 2000, 275:36847-36851.
21. Shimba S., Ishii N., Ohta Y., Ohno T., Watabe Y., Hayashi M., Wada T., Aoyagi T., Tezuka M. Brain and muscle Arnt-like protein-1 (BMAL1), a component of the molecular clock, regulates adipogenesis. Proc. Natl. Acad. Sci. 2005, 102:12071-12076.
22. Nakagawa H., Koyanagi S., Takiguchi T., Kuramoto Y., Soeda S., Shimeno H., Higuchi S., Ohdo S. 24-hour oscillation of mouse methionine aminopeptidase2, a regulator of tumor progression, is regulated by clock gene proteins. Cancer Res. 2004, 64:8328-8333.
23. Koyanagi S., Kuramoto Y., Nakagawa H., Aramaki H., Ohdo S., Soeda S., Shimeno H. A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumor cells. Cancer Res. 2003, 63:7277-7283.
24. Gachon F., Olela F.F., Schaad O., Descombes P., Schibler U. The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. Cell Metab. 2006, 4:25-36.
25. Takiguchi T., Tomita M., Matsunaga N., Nakagawa N., Koyanagi S., Ohdo S. Molecular basis for rhythmic expression of CYP3A4 in serum-shocked HepG2 cells. Pharmacogenet. Genomics 2007, 17(12):1047-1056.
26. Matsunaga N., Ikeda M., Takiguchi T., Koyanagi S., Ohdo S. The molecular mechanism regulating 24-hour rhythm of CYP2E1 expression in the mouse liver. Hepatology 2008, 48(1):240-251.
27. Murakami Y., Higashi Y., Matsunaga N., Koyanagi S., Ohdo S. Circadian clock-controlled intestinal expression of the multidrug-resistance gene mdr1a in mice. Gastroenterology 2008, 135(5):1636-1644.
28. Mrosovsky N. Problems in interpreting the effects of drugs on circadian rhythms. Physiology and Pharmacology of Biological Rhythms 1997, 415-434. Springer-Verlag, Berlin Heidelberg. P.H. Redfern, B. Lemmer (Eds.).
29. Moore R.Y. Chemical neuroanatomy of the mammalian circadian system. Physiology and Pharmacology of Biological Rhythms 1997, 79-93. Springer-Verlag, Berlin Heidelberg. P.H. Redfern, B. Lemmer (Eds.).
30. Shigeyoshi Y., Taguchi K., Yamamoto S., Takekida S., Yan L., Tei H., Moriya T., Shibata S., Loros J.J., Dunlap J.C., Okamura H. Light-induced resetting of a mammalian circadian clock is associated with rapid induction of the mPer1 transcript. Cell 1997, 91:1043-1053.
31. Ohdo S., Ogawa N., Nakano S., Higuchi S. Influence of feeding schedule on the chronopharmacological aspects of sodium valproate in mice. J. Pharmacol. Exp. Ther. 1996, 278(1):74-81.
32. Lewy A.J. Melatonin as a marker and phase-resetter of circadian rhythms in humans. Melatonin after Four Decades. An Assessment of its Potential 1999, 425-434. Kluwer Academic/Plenum Publishers, New York. J. Olcese (Ed.).
33. Ceresa F., Angeli A., Boccuzzi A., Molino G. Once-a-day neurally stimulated and basal ACTH secretion phases in man and their responses to corticoid inhibition. J. Clin. Endocrinol. Metab. 1969, 29:1074-1082.
34. Smolensky M.H., D'Alozo G.E. Progress in the chronotherapy of nocturnal asthma. Physiology and Pharmacology of Biological Rhythms 1997, 205-249. Springer-Verlag, Berlin Heidelberg. P.H. Redfern, B. Lemmer (Eds.).
35. Reinberg A., Smolensky M.H., D'Alonzo G.E., McGovern J.P. Chronobiology and asthma. III. Timing corticotherapy to biological rhythms to optimize treatment goals. J. Asthma 1988, 25:219-248.
36. Reinberg A. Chronopharmacology of corticosteroids and ACTH. Chronopharmacology. Cellular and Biochemical Interactions 1989, 137-178. Marcel Dekker, New York. B. Lemmer (Ed.).
37. Reinberg A., Pauchet F., Ruff F., Gervais A., Smolensky M.H., Levi F., Gervais P., Chaouat D., Abella M.L., Zidani R. Comparison of once-daily evening versus morning sustained-release theophylline dosing for nocturnal asthma. Chronobiol. Int. 1987, 4(3):409-419.
38. Levy F. Circadian chronotherapy for human cancers. Lancet Oncol. 2001, 2:307-315.
39. Levy F., Zidani R., Misset J.L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997, 350:681-686.
40. Hrushesky W.J. Circadian timing of cancer chemotherapy. Science 1985, 228:73-75.
41. Dagan Y. Circadian rhythm sleep disorders (CRSD) in psychiatry - a review. Isr. J. Psychiatry Relat. Sci. 2002, 39(1):19-27.
42. Wirz-Justice A., Cajochen C., Nussbaum P. A schizophrenic patient with an arrhythmic circadian rest-activity cycle. Psychiatry Res. 1997, 73:83-90.
43. Dagan Y. Sleep wake schedule disorders as a possible side effect of CNS medications. Chronobiol. Int. 1999, 16:25.
44. Wirz-Justice A., Werth E., Savaskan E., Knoblauch V., Gasio P.F., Müller-Spahn F. Haloperidol disrupts, clozepine reinstates the circadian rest-activity cycle in a patient with early-onset Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2000, 14:212-215.
45. Ayalon L., Hermesh H., Dagan Y. Case study of circadian rhythm sleep disorder following haloperidol treatment: reversal by risperidone and melatonin. Chronobiol. Int. 2002, 19(5):947-959.
46. Hermesh H., Lemberg H., Abadi J., Dagan Y. Circadian rhythm sleep disorders (CRSD) as a possible side effect of fluvoxamine. CNS Spectr. 2001, 6:511-513.
47. Takane H., Ohdo S., Yamada T., Yukawa E., Higuchi S. Chronopharmacology of antitumor effect induced by interferon-β in tumor-bearing mice. J. Pharmacol. Exp. Ther. 2000, 294:746-752.
48. Ohdo S., Wang D.S., Koyanagi S., Takane H., Inoue K., Aramaki H., Yukawa E., Higuchi S. Basis for dosing time-dependent changes in the antiviral activity of interferon-β in mice. J. Pharmacol. Exp. Ther. 2000, 294:488-493.
49. Nakagawa H., Takiguchi T., Nakamura M., Furuyama A., Koyanagi S., Aramaki H., Higuchi S., Ohdo S. Basis for dosing time-dependent change in the anti-tumor effect of imatinib in mice. Biochem. Pharmacol. 2006, 72(10):1237-1245.
50. Ohdo S., Makinosumi T., Ishizaki T., Yukawa E., Higuchi S., Nakano S., Ogawa N. Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice. J. Pharmacol. Exp. Ther. 1997, 283:1383-1388.
51. Reinberg A., Smolensky M. Circadian changes of drug disposition in man. Clin. Pharmacokinet. 1982, 7:401-420.
52. Bruguerolle B. Chronopharmacokinetics: current status. Clin. Pharmacokinet. 1998, 35:83-94.
53. Moore J.G., Englert E. Circadian rhythm of gastric acid secretion in man. Nature 1970, 226:1261-1262.
54. Bloom P.B., Filion R.D., Stunkard A.J., Fox S., Stellar E. Gastric and duodenal motility, food intake and hunger measured in man during a 24-h period. Am. J. Dig. Dis. 1970, 15:719-725.
55. Goo R.H., Moore J.G., Greenberg E., Alazraki N.P. Circadian variation in gastric emptying of meals in humans. Gastroenterology 1987, 93(3):515-518.
56. Belanger P., Bruguerolle B., Labrecque G. Rhythms in pharmacokinetics: Absorption, distribution, metabolism and excretion. Physiology and Pharmacology of Biological Rhythms 1997, 177-204. Springer-Verlag, Heidelberg. P.H. Redfern, B. Lemmer (Eds.).
57. Labrecque G., Belanger P. Biological rhythms in the absorption, distribution, metabolism and excretion of drugs. Pharmacol. Ther. 1991, 52:95-107.
58. Ohdo S., Nakano S., Ogawa N. Circadian changes of valproate kinetics depending on meal condition in humans. J. Clin. Pharmacol. 1992, 32(9):822-826.
59. Bruguerolle B., Giaufre E., Prat M. Temporal variations in transcutaneous passage of drugs: the example of lidocaine in children and in rats. Chronobiol. Int. 1991, 8:277-282.
60. Ohdo S., Grass G.M., Lee V.H. Improving the ocular to systemic ratio of topical timolol by varying the dosing time. Invest. Ophthalmol. Vis. Sci. 1991, 32:2790-2798.
61. Anderson N.H., Devlin A.M., Graham D., Morton J.J., Hamilton C.A., Reid J.L., Schork N.J., Dominiczak A.F. Telemetry for cardiovascular monitoring in a pharmacological study: new approaches to data analysis. Hypertension 1999, 33:248-255.
62. Pleschka K., Heinrich A., Witte K., Lemmer B. Diurnal and seasonal changes in sympathetic signal transduction in cardiac ventricles of European hamsters. Am. J. Physiol. 1996, 270:304-309.
63. Bruguerolle B., Arnaud C., Levi F., Focan C., Touitou Y., Bouvenot G. Physiopathological alterations of alpha 1 acid glycoprotein temporal variations: implications for chronopharmacology. Alpha 1 Acid Glycoprotein: Genetics, Biochemistry, Physiological Functions and Pharmacology 1989, 199-214. Alan R Liss, Inc., New York. P. Baumann, C.B. Eap, W.E. Muller, J.P. Tillement (Eds.).
64. Nakano S., Watanabe H., Nagai K., Ogawa N. Circadian stage-dependent changes in diazepam kinetics. Clin. Pharmacol. Ther. 1984, 36(2):271-277.
65. Bruguerolle B. Temporal variations in tissular and plasma protein binding of drugs with special references to their erythrocyte penetration as mechanisms involved in chronopharmacological effects. Membranes and Circadian Rhythms 1996, 159-167. Springer-Verlag, Heidelberg. T. Vandendriessche, J.L. Guisset, G. Petiau-de-vries (Eds.).
66. Ando H., Yanagihara H., Sugimoto K., Hayashi Y., Tsuruoka S., Takamura T., Kaneko S., Fujimura A. Daily rhythms of P-glycoprotein expression in mice. Chronobiol. Int. 2005, 22:655-665.
67. Saito H., Terada T., Shimakura J., Katsura T., Inui K. Regulatory mechanism governing the diurnal rhythm of intestinal H+/peptide cotransporter 1 (PEPT1). Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 295(2):G395-G402.
68. Feuers R.J., Scheving L.E. Chronobiology of hepatic enzymes. Ann. Rev. Chronopharmacol. 1988, 4:209-254.
69. Belanger P.M., Labrecque G. Temporal aspects of drug metabolism. Chronopharmacology: Cellular and Biochemical Interactions 1991, 15-34. Marcel Dekker, Basel. B. Lemmer (Ed.).
70. Ohno M., Yamaguchi I., Ito T., Saiki K., Yamamoto I., Azuma J. Circadian variation of the urinary 6 beta-hydroxycortisol to cortisol ratio that would reflect hepatic CYP3A activity. Eur. J. Clin. Pharmacol. 2000, 55:861-865.
71. Shaw G.L., Falk R.T., Caporaso N.E., Issaq H.J., Kase R.G., Fox S.D., Tucker M.A. Effect of diurnal variation on debrisoquine metabolic phenotyping. J. Nat. Cancer. Inst. 1990, 82:1573-1575.
72. Lemmer B., Nold G. Circadian changes in estimated hepatic blood flow in healthy subjects. Br. J. Clin. Pharmacol. 1991, 32(5):627-629.
73. Cambar J., Cal J.C., Tranchot J. Renal excretion: rhythms in physiology and pathology. Biological Rhythms in Clinical and Laboratory Medicine 1992, 470-482. Springer-Verlag, Paris. Y. Touitou, E. Haus (Eds.).
74. Reinberg A., Clench J., Ghata J., Halberg F., Abulker C., Dupont J., Zagula-Mally Z. Circadian rhythms in the urinary excretion of salicylate (chronopharmacokinetics) in healthy adults. CR Acad. Sci. Hebd. Seances Acad. Sci. D. 1975, 280:1697-1699.
75. Detli L., Spring P. Diurnal variations in the elimination rate of sulphonamide in man. Helv. Med. Acta. 1966, 4:921-926.
76. Le Brun M., Grenier L., Bergeron M.G., Thibault L., Labrecque G., Beauchamp D. Effect of fasting on temporal variation in the nephrotoxicity of amphotericin B in rats. Antimicrob. Agents Chemother. 1999, 43:520-524.
77. Beauchamp D., Guimont C., Grenier L., LeBrun M., Tardif D., Gourde P., Bergeron M.G., Thibault L., Labrecque G. Time-restricted feeding schedules modify temporal variation of gentamicin experimental nephrotoxicity. Antimicrob. Agents Chemother. 1997, 41:1468-1474.
78. Ohdo S., Nakano S., Ogawa N. Circadian stage-dependent changes in valproate kinetics and application to dosage adjustment. Clin. Pharmacol. 1990, 6:108-112.
79. Chrystyn H., Ellis J.W., Mulley B.A., Peake M.D. Bayesian derived predictions for twice daily theophylline under outpatient conditions and an assessment of optimal sampling times. Br. J. Clin. Pharmacol. 1989, 27(2):215-221.
80. Ohdo S., Nakano S., Ogawa N. Chronopharmacokinetics of valproic acid following constant-rate administration in mice. Chronobiol. Int. 1991, 8(1):35-43.
81. Altinok A., Levi F., Goldbeter A. Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling. Eur. J. Pharm. Sci. 2009, 36(1):20-38.
82. Uematsu T., Nakano M., Kosuge K., Kanamaru M., Nakashima M. The pharmacokinetics of the beta 2-adrenoceptor agonist, tulobuterol, given transdermally and by inhalation. Eur. J. Clin. Pharmacol. 1993, 44(4):361-364.
83. Electronic Orange Book 2003, FDA, Administration, Washington, DC, F.a. D.
84. Innominato P.F., Focan C., Gorlia T., Moreau T., Garufi C., Waterhouse J., Giacchetti S., Coudert B., Iacobelli S., Genet D., Tampellini M., Chollet P., Lentz M.A., Mormont M.C., Lévi F., Bjarnason G.A. Chronotherapy Group of the European Organization for Research and Treatment of Cancer. Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res. 2009, 69(11):4700-4707.
85. Wollnik F., Brysch W., Uhlmann E., Gillardon F., Bravo R., Zimmermann M., Schlingensiepen K.H., Herdegen T. Block of c-Fos and JunB expression by antisense oligonucleotides inhibits light-induced phase shifts of the mammalian circadian clock. Eur. J. Neurosci. 1995, 7:388-393.
86. Terazono H., Hamdan A.M., Matsunaga N., Hayasaka N., Kaji H., Egawa T., Makino K., Shigeyoshi Y., Koyanagi S., Ohdo S. Modulatory effects of 5-fluorouracil on the rhythmic expression of circadian clock genes: a possible mechanism of chemotherapy-induced circadian rhythm disturbances. Biochem. Pharmacol. 2008, 75:1616-1622.
87. Fattovich G., Giustina G., Favarato S., Ruol A. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon. J. Hepatol. 1996, 24:38-47.
88. Janssen H.L.A., Brouwer J.T., van der Mast R.C., Schalm S.W. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J. Hepatol. 1994, 21:241-243.
89. Bocci V. Administration of interferon at night may increase its therapeutic index. Cancer Drug Deliv. 1985, 2:313-318.
90. Abo T., Kawate T., Itoh K., Kumagai K. Studies on the bioperiodicity of the immune response. 1. Circadian rhythms of human T, B and K cell traffic in the peripheral blood. J. Immunol. 1981, 126:1360-1363.
91. Bertouch J.V., Roberts-Thomson P.J., Bradley J. Diurnal variation of lymphocyte subsets identified by monoclonal antibodies. Brit. Med. J. 1983, 286:1171-1172.
92. Haus E., Lakatua D.J., Swoyer J., Sackett-Lundeen L. Chronobiology in hematology and immunology. Am. J. Anat. 1983, 168:467-517.
93. Ritchie A.W., Oswald I., Micklem H.S., Boyd J.E., Elton R.A., Jazwinska E., James K. Circadian variation of lymphocyte subpopulations: a study with monoclonal antibodies. Brit. Med. J. 1983, 286:1773-1775.
94. Bocci V. Distribution catabolism and pharmacokinetics of interferons. Interferon 1985, 47-72. Elsevier, Amsterdam. N.B. Finter, R. Oldham (Eds.).
95. Scott G.M., Ward R.J., Wright D.J., Robinson J.A., Onwubalili J.K., Gauci C.L. Effects of cloned interferon 2 ln normal volunteers: febrile reactions and changes in circulating corticosteroids and trace metals. Antimicrob. Agents Chemother. 1983, 23:589-592.
96. Scott G.M., Secher D.S., Flowers D., Bate J., Cantell K., Tyrrell D.A. Toxicity of interferon. Brit. Med. J. 1981, 282:1345-1348.
97. Gresser I., Guy-Grand D., Maury C., Maunory M.T. Interferon induces peripheral lymphadenopathy in mice. J. Immunol. 1981, 127:1569-1575.
98. Gallatin W.M., Weissman I.L., Butcher E.G. A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature 1983, 304:30-34.
99. Eskola J., Frey H., Molnar G., Soppi E. Biological rhythm of cell-mediated immunity in man. Clin. Exp. Immunol. 1976, 26:253-257.
100. Cove-Smith J.R., Kabler P., Pownall R., Knapp M.S. Circadian variation in an immune response in man. Brit. Med. J. 1978, 2:253-254.
101. Damiola F., Le Minh N., Preitner N., Kornmann B., Fleury-Olela F., Schibler U. Restricted feeding uncouples circadian oscillators in peripheral tissues from the central pacemaker in the suprachiasmatic nucleus. Genes Dev. 2000, 14:2950-2961.
102. Takahashi J.S. Molecular neurobiology and genetics of circadian rhythms in mammals. Annu. Rev. Neurosci. 1995, 18:531-553.
103. Akiyama M., Kouzu Y., Takahashi S., Wakamatsu H., Moriya T., Maetani M., Watanabe S., Tei H., Sakaki Y., Shibata S. Inhibition of light- or glutamate-induced mPer1 expression represses the phase shifts into the mouse circadian locomotor and suprachiasmatic firing rhythms. J. Neurosci. 1999, 19:1115-1121.
104. Horikawa K., Yokota S., Fuji K., Akiyama M., Moriya T., Okamura H., Shibata S. Nonphotic entrainment by 5-HT1A/7 receptor agonists accompanied by reduced Per1 and Per2 mRNA levels in the suprachiasmatic nuclei. J. Neurosci. 2000, 20:5867-5873.
105. Aschoff J. Comparative physiology: diurnal rhythms. Ann. Rev. Physiol. 1963, 25:581-600.
106. Boulos Z., Terman M. Food availability and daily biological rhythms. Neurosci. Biobehav. Rev. 1980, 4:119-131.
107. Krieger D.T., Hauser H., Krey L.C. Suprachiasmatic nuclear lesions do not abolish food-shifted circadian adrenal and temperature rhythmicity. Science 1977, 197:398-399.
108. Krieger D.T. Ventromedial hypothalamic lesions abolish food-shifted circadian adrenal and temperature rhythmicity. Endocrinology 1980, 106:649-654.
109. Honma K., Noe Y., Honma S., Katsuno Y., Hiroshige T. Roles of paraventricular catecholamines in feeding-associated corticosterone rhythm in rats. Am. J. Physiol. 1992, 262:E948-E955.
110. Saito M., Nishimura K., Kato H. Modifications of circadian cortisol rhythm by cyclic and continuous total enteral nutrition. J. Nutr. Sci. Vitaminol. 1989, 35:639-647.
111. Nishimura K., Kato H., Saito M. Effects of cyclic and continuous total enteral nutrition on 24-h rhythms of body temperature and urinary excretions. J. Nutr. Sci. Vitaminol. 1992, 38(2):117-125.
112. Matsunaga N., Nakamura N., Yoneda N., Qin N.T., Terazono H., To H., Higuchi S., Ohdo S. Influence of feeding schedule on 24-h rhythm of hepatotoxicity induced by acetaminophen in mice. J. Pharmacol. Exp. Ther. 2004, 311(2):594-600.
113. Akagi T., Ushinohama K., Kage Y., Ishizaki T., Makinosumi T., Yamauchi A., Taguchi Y., Inoue K., Yukawa E., Higuchi S., Ohdo S. Cell kinetics-dependent antitumor effect of irinotecan hydrochloride induced by the synchronizing effect of hydroxyurea: cell kinetics and dosing time. Life Sci. 2003, 72(10):1183-1197.